Novogen Limited (KZIA)
(Delayed Data from NSDQ)
$0.25 USD
-0.01 (-4.65%)
Updated Jun 12, 2024 03:59 PM ET
After-Market: $0.25 0.00 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Novogen Limited [KZIA]
Reports for Purchase
Showing records 21 - 40 ( 46 total )
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Simcere License is a Strong Vote of Confidence in Paxalisib; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
All in on GBM AGILE, but eyes on brain mets
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
All in on GBM AGILE, but eyes on brain mets
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
A Unique PI3K Inhibitor for Brain Tumors; Initiate With Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Cantrixil final Phase I data reported
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Phase IIa shows good safety, consistent efficacy
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Phase IIa shows good safety, consistent efficacy
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Bringing a vetted drug class to the brain
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Bringing a vetted drug class to the brain
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Bringing a vetted drug class to the brain
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Higher MTD, new collaboration for GDC-0084
Provider: Edison Investment Research Limited
Analyst: HULME D
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Higher MTD, new collaboration for GDC-0084
Provider: Edison Investment Research Limited
Analyst: HULME D
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Higher MTD, new collaboration for GDC-0084
Provider: Edison Investment Research Limited
Analyst: HULME D
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Cantrixil efficacy data presented at AACR
Provider: Edison Investment Research Limited
Analyst: HULME D